Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Merck

8% growth in the quarter driven by Oncology and Vaccines

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
1Q Revenues: $10.8 billion, (+8%)
1Q Earnings: $2.9 billion (earnings were $736 million 1Q18)
Comments: Growth in the quarter was driven by Oncology and Vaccines. International sales represented 58% of total sales in the quarter led by China, with $725 million in sales, up 58%. Keytruda sales were up 55% to $2.3 billion. Januvia sales were $1.4 billion, down 5%. Gardasil sales were up 27% to $838 million. Proquad, M-M-R II and Varivax sales were $496 million, up 27%. Bridion sales were up 25% to $255 million. Zetia/Vytorin sales were down 50% to $238 million. Isentress sales were down 9% to $255 million. Simponi sales were down 10% to $208 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters